Subclinical synovitis impact on the progression of lupus joint disease: A 10-year longitudinal multicenter study
CONCLUSIONS: The finding of subclinical synovitis in patients with systemic lupus erythematosus is associated with the development of joint disease progression both clinically and ultrasonographically.PMID:38491423 | DOI:10.1177/09612033241240584 (Source: Lupus)
Source: Lupus - March 16, 2024 Category: Rheumatology Authors: Carlos A Guill én-Astete Marcelino Revenga-Mart ínez Antonio C Zea-Mendoza Mar ía E Brito-Brito Pablo Zurita-Prada Claudia Urrego-Laur ín Lourdes Villalobos-S ánchez Nuria Garc ía-Montes M ónica Vázquez-Díaz Source Type: research
Subclinical synovitis impact on the progression of lupus joint disease: A 10-year longitudinal multicenter study
CONCLUSIONS: The finding of subclinical synovitis in patients with systemic lupus erythematosus is associated with the development of joint disease progression both clinically and ultrasonographically.PMID:38491423 | DOI:10.1177/09612033241240584 (Source: Lupus)
Source: Lupus - March 16, 2024 Category: Rheumatology Authors: Carlos A Guill én-Astete Marcelino Revenga-Mart ínez Antonio C Zea-Mendoza Mar ía E Brito-Brito Pablo Zurita-Prada Claudia Urrego-Laur ín Lourdes Villalobos-S ánchez Nuria Garc ía-Montes M ónica Vázquez-Díaz Source Type: research
Subclinical synovitis impact on the progression of lupus joint disease: A 10-year longitudinal multicenter study
CONCLUSIONS: The finding of subclinical synovitis in patients with systemic lupus erythematosus is associated with the development of joint disease progression both clinically and ultrasonographically.PMID:38491423 | DOI:10.1177/09612033241240584 (Source: Lupus)
Source: Lupus - March 16, 2024 Category: Rheumatology Authors: Carlos A Guill én-Astete Marcelino Revenga-Mart ínez Antonio C Zea-Mendoza Mar ía E Brito-Brito Pablo Zurita-Prada Claudia Urrego-Laur ín Lourdes Villalobos-S ánchez Nuria Garc ía-Montes M ónica Vázquez-Díaz Source Type: research
Global tuberculosis disease and infection in systemic lupus erythematosus patients: A systematic review and meta-analysis
CONCLUSION: TB prevalence in SLE was relatively high and associated with GC. Awareness of TB and lowering GC dose are warranted to alleviate the TB burden in SLE.PMID:38490946 | DOI:10.1177/09612033241239504 (Source: Lupus)
Source: Lupus - March 15, 2024 Category: Rheumatology Authors: Guntur Darmawan Lie Monica Sherine Liman Suryo Anggoro Kusumo Wibowo Laniyati Hamijoyo Lika Apriani Nur Atik Bachti Alisjahbana Edhyana Sahiratmadja Source Type: research
Global tuberculosis disease and infection in systemic lupus erythematosus patients: A systematic review and meta-analysis
CONCLUSION: TB prevalence in SLE was relatively high and associated with GC. Awareness of TB and lowering GC dose are warranted to alleviate the TB burden in SLE.PMID:38490946 | DOI:10.1177/09612033241239504 (Source: Lupus)
Source: Lupus - March 15, 2024 Category: Rheumatology Authors: Guntur Darmawan Lie Monica Sherine Liman Suryo Anggoro Kusumo Wibowo Laniyati Hamijoyo Lika Apriani Nur Atik Bachti Alisjahbana Edhyana Sahiratmadja Source Type: research
Glucocorticoid-free remission in patients with SLE in the era of biologics: Immune complex disease is likely to benefit from current medications
CONCLUSION: In the era of biologics, CR off C was achieved in 28.3% of the patient cohort requiring the start or increase of glucocorticoids for disease activity, with a relatively low rate of flares, suggesting that glucocorticoid-free clinical remission is an achievable target in SLE. IC disease, represented by male sex or nephritis, is likely to benefit from currently available medications.PMID:38470859 | DOI:10.1177/09612033241238055 (Source: Lupus)
Source: Lupus - March 12, 2024 Category: Rheumatology Authors: Hiroshi Oiwa Takeshi Suga Yohei Hosokawa Kei Araki Source Type: research
Glucocorticoid-free remission in patients with SLE in the era of biologics: Immune complex disease is likely to benefit from current medications
CONCLUSION: In the era of biologics, CR off C was achieved in 28.3% of the patient cohort requiring the start or increase of glucocorticoids for disease activity, with a relatively low rate of flares, suggesting that glucocorticoid-free clinical remission is an achievable target in SLE. IC disease, represented by male sex or nephritis, is likely to benefit from currently available medications.PMID:38470859 | DOI:10.1177/09612033241238055 (Source: Lupus)
Source: Lupus - March 12, 2024 Category: Rheumatology Authors: Hiroshi Oiwa Takeshi Suga Yohei Hosokawa Kei Araki Source Type: research
Glucocorticoid-free remission in patients with SLE in the era of biologics: Immune complex disease is likely to benefit from current medications
CONCLUSION: In the era of biologics, CR off C was achieved in 28.3% of the patient cohort requiring the start or increase of glucocorticoids for disease activity, with a relatively low rate of flares, suggesting that glucocorticoid-free clinical remission is an achievable target in SLE. IC disease, represented by male sex or nephritis, is likely to benefit from currently available medications.PMID:38470859 | DOI:10.1177/09612033241238055 (Source: Lupus)
Source: Lupus - March 12, 2024 Category: Rheumatology Authors: Hiroshi Oiwa Takeshi Suga Yohei Hosokawa Kei Araki Source Type: research
Comparison of late-onset and non-late-onset systemic lupus erythematosus individuals in a real-world electronic health record cohort
Conclusion: LO-SLE individuals may be less likely to fit an expected course for SLE with less frequent positive autoantibodies at diagnosis and lower rates of nephritis, even after adjusting for race. Understanding how age impacts SLE disease presentation could help reduce diagnostic delays in SLE.PMID:38454796 | DOI:10.1177/09612033241238052 (Source: Lupus)
Source: Lupus - March 8, 2024 Category: Rheumatology Authors: Ganiat Adeogun Alex Camai Ashley Suh Lee Wheless April Barnado Source Type: research
Early add-on use of belimumab as induction therapy for patients with childhood-onset systemic lupus erythematosus
Lupus. 2024 Mar 8:9612033241238867. doi: 10.1177/09612033241238867. Online ahead of print.NO ABSTRACTPMID:38456833 | DOI:10.1177/09612033241238867 (Source: Lupus)
Source: Lupus - March 8, 2024 Category: Rheumatology Authors: Shun Hashimoto Masashi Fujita Tomomi Aizawa Shojiro Watanabe Koji Tsugawa Hiroshi Tanaka Source Type: research
Using combination of albumin to fibrinogen ratio and prognostic nutritional index model for predicting disease activity in patients with systemic lupus erythematosus
Conclusion: These findings suggest that predictive model based on combination of AFR and PNI may be useful markers to identify active SLE in clinical practice.PMID:38457835 | DOI:10.1177/09612033241238505 (Source: Lupus)
Source: Lupus - March 8, 2024 Category: Rheumatology Authors: Hongshuai Zhao Zikun Huang Shiqian Wang Peng Fu Biqi Fu Yang Guo Junming Li Qing Luo Source Type: research
Childhood adverse experiences and clinical manifestations in women with systemic lupus erythematosus
CONCLUSION: Individuals with a positive history of ACE have significant associations with certain clinical manifestations of SLE and subtypes of ACE, underscoring the importance of preventing childhood trauma to improve adult health. Further studies are needed to elucidate the impact of ACE on adult health.PMID:38457921 | DOI:10.1177/09612033241238056 (Source: Lupus)
Source: Lupus - March 8, 2024 Category: Rheumatology Authors: Elisa Esteves Rossini Jonatas Lourival Zanoveli Cunha Gabriela L B Costa Karin Araujo Melo Jos é Pedro Cassemiro Micheleto Vanessa Miranda Pereira Fausto La ís Quintiliano Pedroza Thiago Sotero Fragoso Valfrido Le ão de Melo Neto Michelle Jacintha Cava Source Type: research
Comparison of late-onset and non-late-onset systemic lupus erythematosus individuals in a real-world electronic health record cohort
Conclusion: LO-SLE individuals may be less likely to fit an expected course for SLE with less frequent positive autoantibodies at diagnosis and lower rates of nephritis, even after adjusting for race. Understanding how age impacts SLE disease presentation could help reduce diagnostic delays in SLE.PMID:38454796 | DOI:10.1177/09612033241238052 (Source: Lupus)
Source: Lupus - March 8, 2024 Category: Rheumatology Authors: Ganiat Adeogun Alex Camai Ashley Suh Lee Wheless April Barnado Source Type: research
Early add-on use of belimumab as induction therapy for patients with childhood-onset systemic lupus erythematosus
Lupus. 2024 Mar 8:9612033241238867. doi: 10.1177/09612033241238867. Online ahead of print.NO ABSTRACTPMID:38456833 | DOI:10.1177/09612033241238867 (Source: Lupus)
Source: Lupus - March 8, 2024 Category: Rheumatology Authors: Shun Hashimoto Masashi Fujita Tomomi Aizawa Shojiro Watanabe Koji Tsugawa Hiroshi Tanaka Source Type: research
Using combination of albumin to fibrinogen ratio and prognostic nutritional index model for predicting disease activity in patients with systemic lupus erythematosus
Conclusion: These findings suggest that predictive model based on combination of AFR and PNI may be useful markers to identify active SLE in clinical practice.PMID:38457835 | DOI:10.1177/09612033241238505 (Source: Lupus)
Source: Lupus - March 8, 2024 Category: Rheumatology Authors: Hongshuai Zhao Zikun Huang Shiqian Wang Peng Fu Biqi Fu Yang Guo Junming Li Qing Luo Source Type: research
